SOW
ZNTL icon

State of Wyoming’s Zentalis Pharmaceuticals ZNTL Stock Holding History

State of Wyoming’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$91K Sell
18,756
-9,710
-34% -$38.8K 0.01% 1426
2026
Q1 		$66.6K Buy
+28,466
New +$73.5K 0.01% 1434
2025
Q3 		– Sell
-73,797
Closed -$85.6K – 2092
2025
Q2 		$85.6K Buy
73,797
+28,621
+63% +$37.7K 0.01% 1360
2025
Q1 		$71.8K Buy
45,176
+10,460
+30% +$22.6K 0.01% 1313
2024
Q4 		$105K Buy
34,716
+19,262
+125% +$63.1K 0.01% 1158
2024
Q3 		$56.9K Buy
+15,454
New +$56.2K 0.01% 1378
2021
Q4 		– Sell
-83
Closed -$6K – 1999
2021
Q3 		$6K Sell
83
-597
-88% -$34.4K ﹤0.01% 1081
2021
Q2 		$36K Buy
680
+387
+132% +$20.7K 0.02% 826
2021
Q1 		$13K Buy
+293
New +$12.6K 0.02% 368

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

State of Wyoming's ZNTL Position: Q2 2026 in Review

State of Wyoming reduced its Zentalis Pharmaceuticals (ZNTL) stake by 34% in Q2 2026, selling an estimated $38.8K and leaving 18,756 shares worth $91K. The position accounts for 0.01% of the portfolio, ranked #1426.

State of Wyoming first reported a position in ZNTL in Q1 2021 and has held it in 9 quarters since. The position peaked at $105K in Q4 2024. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • State of Wyoming held 18,756 shares of Zentalis Pharmaceuticals worth $91K as of Q2 2026.
  • State of Wyoming sold 9,710 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $38.8K.
  • Zentalis Pharmaceuticals made up 0.01% of State of Wyoming's portfolio in Q2 2026, its #1426 holding.
  • State of Wyoming first reported a position in Zentalis Pharmaceuticals in Q1 2021 and has held it in 9 quarters since.
  • State of Wyoming's Zentalis Pharmaceuticals position peaked at $105K in Q4 2024.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on State of Wyoming's 13F filing for Q2 2026, filed 6 Aug 2026.